Gene · 2213
Papers4,232
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 4,232
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. | Cancer Med | 2023 | 37840445 | PubTator, text mining | PubMed |
| Development of a Cytotoxic Antibody-Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells. | Int J Mol Sci | 2023 | 37834445 | PubTator, text mining | PubMed |
| The Involvement of Neuroinflammation in the Onset and Progression of Parkinson's Disease. | Int J Mol Sci | 2023 | 37834030 | PubTator, text mining | PubMed |
| Mitogen-Activated Protein Kinase and Exploratory Nuclear Receptor Crosstalk in Cancer Immunotherapy. | Int J Mol Sci | 2023 | 37833991 | PubTator, text mining | PubMed |
| Analytical and Functional Similarity of the Biosimilar Candidate ABP 654 to Ustekinumab Reference Product. | Drugs R D | 2023 | 37831372 | PubTator, text mining | PubMed |
| Anti-Inflammatory and Immunomodulatory Effect of High-Dose Immunoglobulins in Children: From Approved Indications to Off-Label Use. | Cells | 2023 | 37830631 | PubTator, text mining | PubMed |
| Influence of Humoral Response Against GnRH, Generated by Immunization with a Therapeutic Vaccine Candidate on the Evolution of Patients with Castration-Sensitive Prostate Adenocarcinoma. | Technol Cancer Res Treat | 2023 | 37828833 | PubTator, text mining | PubMed |
| Don't eat me/eat me signals as a novel strategy in cancer immunotherapy. | Heliyon | 2023 | 37822610 | PubTator, text mining | PubMed |
| Association between immunoglobulin G N-glycosylation and lupus nephritis in female patients with systemic lupus erythematosus: a case-control study. | Front Immunol | 2023 | 37809087 | PubTator, text mining | PubMed |
| Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE). | BMC Rheumatol | 2023 | 37807057 | PubTator, text mining | PubMed |
| ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1. | Cancer Immunol Immunother | 2023 | 37796298 | PubTator, text mining | PubMed |
| Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. | Front Immunol | 2023 | 37795079 | PubTator, text mining | PubMed |
| Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes. | Front Immunol | 2023 | 37790943 | PubTator, text mining | PubMed |
| Lupus clinical trials and the promise of future therapies. | Rheumatol Immunol Res | 2023 | 37781678 | PubTator, text mining | PubMed |
| Impact of estrogen on IgG glycosylation and serum protein glycosylation in a murine model of healthy postmenopause. | Front Endocrinol (Lausanne) | 2023 | 37766692 | PubTator, text mining | PubMed |
| In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG. | Pathogens | 2023 | 37764916 | PubTator, text mining | PubMed |
| Efficacy and Safety of Intravenous Immunoglobulin Treatment in Selected Neurological Diseases-One Centre's Experience Based on the Therapy of 141 Patients. | J Clin Med | 2023 | 37762922 | PubTator, text mining | PubMed |
| The Role of the Spleen and the Place of Splenectomy in Autoimmune Hemolytic Anemia-A Review of Current Knowledge. | Diagnostics (Basel) | 2023 | 37761258 | PubTator, text mining | PubMed |
| Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants. | Antibodies (Basel) | 2023 | 37753968 | PubTator, text mining | PubMed |
| B cell responses to membrane-presented antigens require the function of the mechanosensitive cation channel Piezo1. | Sci Signal | 2023 | 37751477 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2213/papers?page=17